Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)

Spain flag Spain · Delayed Price · Currency is EUR
52.80
+0.05 (0.09%)
May 21, 2025, 5:35 PM CET
-39.86%
Market Cap 2.70B
Revenue (ttm) 767.47M
Net Income (ttm) 140.02M
Shares Out 51.15M
EPS (ttm) 2.74
PE Ratio 19.27
Forward PE 19.31
Dividend 0.94 (1.77%)
Ex-Dividend Date Jul 14, 2025
Volume 64,674
Average Volume 94,588
Open 52.90
Previous Close 52.75
Day's Range 52.75 - 53.50
52-Week Range 45.52 - 94.80
Beta 0.42
RSI 55.32
Earnings Date May 9, 2025

About BME:ROVI

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+,... [Read more]

Sector Healthcare
Founded 1946
Employees 2,197
Stock Exchange Madrid Stock Exchange
Ticker Symbol ROVI
Full Company Profile

Financial Performance

In 2024, BME:ROVI's revenue was 763.75 million, a decrease of -7.93% compared to the previous year's 829.51 million. Earnings were 136.88 million, a decrease of -19.64%.

Financial Statements

News

Laboratorios Farmaceuticos Rovi SA (WBO:ROVI) Q4 2024 Earnings Call Highlights: Navigating ...

Laboratorios Farmaceuticos Rovi SA (WBO:ROVI) Q4 2024 Earnings Call Highlights: Navigating Challenges and Seizing Growth Opportunities

3 months ago - GuruFocus